Veeda Clinical Research Limited
| Market Cap | ₹3,370Cr. | Stock P/E | -9158.9 |
| Current Price | ₹430 | Book Value | ₹169 |
| Lot Size | 100 | 52W Low | ₹ |
| 52W High | ₹ | Demat Account | NSDL\CDSL |
| EPS | -0.06 | ISIN | INE01HQ01026 |
| Debt to Equity | 0.25 | Valuation | ⭐⭐⭐⭐⭐ |
| Face Value | 2 | No. of Shares | 6.3 |
Description
| Buy Price | Minimum Quantity | Amount |
|---|---|---|
| ₹ 400 | 100 | ₹ 40000 |
| Sell Price | Minimum Quantity | Amount |
|---|---|---|
| ₹ 430 | 100 | ₹ 43000 |
Company Overview:
Industry: Medical Equipment/Supplies/Accessories
Incorporation Year: 2004
Website: https://www.veedacr.com/
Company Overview : Veeda Clinical Research Limited is a prominent Contract Research Organization (CRO) based in India, specializing in providing clinical research services to the global pharmaceutical and biotechnology industries. Established in 2004, Veeda offers a comprehensive range of services including bioavailability and bioequivalence studies, phase I-IV clinical trials, clinical data management, pharmacovigilance, and statistical analysis. With state-of-the-art facilities and adherence to international regulatory standards, Veeda ensures high-quality, ethical, and reliable research outputs. The company is committed to advancing healthcare through innovation, scientific excellence, and strong client partnerships, making it a trusted partner for drug development and regulatory submissions worldwide.
Announcement and News
VEEDA CLINICAL RESEARCH awarded as Best Pharmaceutical CRO 2017 by APAC Indian Business Excellence Aw
AHMEDABAD, India – July 3, 2017 — Veeda Clinical Research has been awarded as “Best Pharmaceutical CRO 2017 by APAC Indian Business Excellence Awardsbased in UK. The Indian Excellence Awards 2017 have been created to recognize and reward the outstanding accomplishments made by those within their respective industries. With their inventive thinking and inimitable ways, they have managed to attain phenomenal results. The award goes to the clinical research organization that best demonstrates an ongoing commitment to improving clinical research services in India. This award is a testimony to Veeda’s commitment in supporting all stakeholders – sponsors, investigators, and patients, through highly ethical, transparent and best-in-class services.
Financial Data (IN CR.)
| YEAR | 2024 | 2023 | 2022 |
|---|---|---|---|
| NET SALES | 388.8 | 409.6 | 288 |
| TOTAL INCOME | 408 | 420.2 | 293.1 |
| NET PROFIT | -0.4 | 42.4 | 50.5 |
| SHAREHOLDERS FUND | 1065 | 462.9 | 437.3 |
| TOTAL ASSETS | 2040.2 | 734.8 | 677.5 |
| EPS | -0.06 | 6.73 | 8.01 |
Financial Docs
Profit and Loss (IN CR.)
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Revenue | 288 | 409 | 388 |
| Cost Of Material Consumed | 28 | 33 | 38 |
| Gross Margin | 90.28 | 91.93 | 90.21 |
| OPM | 21.23 | 25.18 | 13.66 |
| Other Income | 39 | 8 | 19 |
| Other Expenses | 111 | 164 | 171 |
| Depreciation & Amortization | 25 | 38 | 53 |
| Profit before tax | 65 | 59 | 3.3 |
| Net Profit Margin | 17.36 | 10.27 | -0.08 |
| EPS in Rs | 9.46 | 8 | -0.04 |
| Finance Cost | 10 | 14 | 14 |
Balance Sheet (IN Cr.)
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Share Capital | 10.57 | 10.5 | 13.599 |
| Reserves | 426 | 452 | 1047 |
| Borrowings | 47 | 48 | 260 |
| Other Liabilities | 168.43 | 202.5 | 473 |
| Total Liabilities | 677 | 735 | 2040.6 |
| Fixed Assets | 185 | 236 | 190 |
| CWIP | 20 | 22 | 33 |
| Investments | 88 | 55 | 80 |
| Other Assets | 278 | 310 | 1610 |
| Total Assets | 677 | 735 | 2040.2 |
Shareholding Pattern
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Basil Private Limitd | 42.07% | 42.07% | 35.52% |
| Bondway investment Inc. | 24.82% | 24.82% | 20.45% |
| Sabre Partners AIF Trust | 5.22% | 5.22% | 4.38% |
| Others | 27.89% | 27.89% | 39.65% |